Relationship of amyloid beta, tau, and alpha synuclein in CSF and the clinical manifestations and severity in patients with dementia.

Not Applicable

Recruiting

• Conditions: Alzheimer' s diease, Dementia with lewy bodies

• Registration Number: JPRN-UMIN000041147
• Lead Sponsor: Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-20
• Last Update Posted: 17 October 2023
• Study Completion: 2025-03-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Patients on strong antithrombotic therapy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To clarify the relationship between the levels of amyloid beta protein, tau protein, and alpha-synuclein in cerebrospinal fluid/blood, clinical disease type, and imaging findings.

Secondary Outcome Measures

Name	Time	Method
To investigate the correlation between the severity of Alzheimer's disease and dementia with Lewy bodies and the levels of cerebrospinal fluid/blood amyloid beta protein, tau protein, and alpha-synuclein.